HCP Live

HIMSS10 Live Twitter Stream

Mar 2, 2010

Couldn't make it to HIMSS? No problem, we've got you covered. Check back for the latest Web exclusives on HIMSS10 sessions.

Couldn't make it to HIMSS? No problem, we've got you covered. Check back for the latest Web exclusives on HIMSS10 sessions. And although we may only be able to attend a fraction of the sessions, our frinds on Twitter will help you stay abreast of all the latest news by covering everything and bringing it right to your computer.

Related Videos

Victor-Kim-MD

Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development

Panagis Galiatsatos, MD: Closing the Gap in Lung Cancer Screening

Antonio Anzueto, MD: Advancing Triple-Therapy Inhalers for COPD

Panagis Galiatsatos, MD

Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication

Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660

Adam Faye, MD: Treating the Older Population With IBD

Related Content

Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab

Lungcast: Live From ATS 2023 with Anne Dixon, MD

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

April 23rd 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis

Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab

Lungcast: Live From ATS 2023 with Anne Dixon, MD

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

April 23rd 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis

Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab

Lungcast: Live From ATS 2023 with Anne Dixon, MD

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

April 23rd 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis

Related Content

Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab

Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab

Live From ATS 2023 with Anne Dixon, MD

Lungcast: Live From ATS 2023 with Anne Dixon, MD

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MD

April 23rd 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis

Guselkumab Bests Placebo in Clinical Remission for Ulcerative Colitis

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.